Latest stories on DMAC
Q3 2026 DiaMedica Therapeutics Inc Earnings Call Transcript
GuruFocus50 · neutralearnings
DiaMedica (DMAC) Q3 2026 Earnings Call Transcript
The Motley Fool63 · neutralearnings
DiaMedica Therapeutics (DMAC) Reports Key Clinical Milestones in Q3 2026, Eyes Q1 2027 DSMB Review
GuruFocus64 · neutralproduct/pr
DiaMedica expects cash to fund operations into Q4 2027 as ReMEDy2 interim analysis approaches in Q1 2027
Seeking Alpha58 · neutralproduct/pr
DiaMedica Therapeutics Inc. (DMAC) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
DiaMedica Therapeutics (DMAC) Reports Q3 EPS In Line with Estimates; Shares Dip 3.4%
GuruFocus44 · neutralearnings
DiaMedica Therapeutics GAAP EPS of -$0.21 in-line
Seeking Alpha52 · neutralearnings
DiaMedica Therapeutics Inc. (DMAC) files 8-K: Items 2.02, 9.01
SEC 8-K50 · neutralgeneral
DiaMedica Therapeutics reports Q3 EPS (21c), consensus (21c)
The Fly50 · neutralearnings
DiaMedica Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Highlights
StockTitan52 · neutralearnings
DiaMedica announces enrollment of 200th patient in ReMEDy2 Phase 2/3 trial
The Fly63 · neutralproduct/pr
DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
StockTitan63 · neutralproduct/pr
DiaMedica (DMAC) Sets Nov. 24 KOL Webinar to Add Interim Results From Two Phase 2 FGR Cohorts
October 20, 2026
MarketChameleon58 · neutralproduct/pr
DiaMedica Therapeutics provides update on FGR trial at KOL event
The Fly56 · neutralproduct/pr
DiaMedica Therapeutics Provides Update on Fetal Growth Restriction Key Opinion Leader Webinar
StockTitan53 · neutralproduct/pr
DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences
StockTitan56 · neutralgeneral
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript
The Motley Fool56 · neutralearnings
DiaMedica anticipates ReMEDy2 interim analysis in Q1 2027 as enrollment surpasses 85% of 200-patient trigger
Seeking Alpha63 · neutralproduct/pr
DiaMedica Therapeutics Inc. (DMAC) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
DiaMedica Expands Equity Incentive Pool With New S-8 Share Registration
TipRanks50 · neutralgeneral
DiaMedica Therapeutics GAAP EPS of -$0.19 beats by $0.01
Seeking Alpha56 · neutralearnings
DiaMedica Therapeutics reports Q2 EPS (19c), consensus (20c)
The Fly47 · neutralearnings